News ArticleApollo Hospitals Completes Rs 11,500 Million Divestment and Announces Senior Management Changes in H1 FY2027
Company finalizes sale of two subsidiaries to Kids Clinic India Limited with receipt of consideration and equity stake; reports unaudited results for six months ended September 30, 2026
Apollo Hospitals Enterprise Limited completed divestment of its subsidiaries Apollo Specialty Hospitals Pvt Ltd and Apollo Fertility Centre Pvt Ltd to Kids Clinic India Ltd for Rs 11,500 million, receiving approximately 9.9% equity in the buyer. The company also reported unaudited financial results for the six months ended 30 September 2026 and announced key senior management changes including cessation of its Hospitals Division CEO effective November 14, 2026.
Apollo Hospitals Enterprise Limited
Investor Presentation
Apollo Hospitals Enterprise Limited has successfully completed the divestment of its subsidiaries Apollo Specialty Hospitals Private Limited and Apollo Fertility Centre Private Limited to Kids Clinic India Limited, receiving Rs 7,650 million in cash and an approximate 9.9% equity stake valued at Rs 3,850 million in the buyer. The company also announced key senior management personnel changes and approved its unaudited financial results for the six months ended 30 September 2026.
The divestment transaction was completed on November 3, 2026, at an enterprise value of approximately Rs 11,500 million. Consequently, Apollo Specialty Hospitals Private Limited and Apollo Fertility Centre Private Limited ceased to be subsidiaries of Apollo Health and Lifestyle Limited, a wholly owned subsidiary of Apollo Hospitals Enterprise Limited.
Regarding senior management, Dr. Madhu Sasidhar, President & CEO – Hospitals Division, will cease to hold his position effective November 14, 2026, upon completion of his employment tenure. Other senior management appointments include Dr. Ritu Garg as CEO for Multi Regions, Dr. N. Venkatesan as Chief Procurement Officer, and Mr. Anand Wasker as Chief Business Officer - International.
The unaudited standalone and consolidated financial results for the three and six months ended 30 September 2026 were approved by the Board. The company reported revenue from operations of Rs 55,590 million for the six months period, with a profit after tax of Rs 8,607 million.
Post-divestment, the functions and regions previously reporting to the Hospitals Division CEO will report to the Project Management Office under the Managing Director's guidance.
Highlights
- Divestment completed on November 3, 2026, at Rs 11,500 million enterprise value.
- Received Rs 7,650 million cash and 9.9% equity stake in Kids Clinic India Limited valued at Rs 3,850 million.
- Apollo Specialty Hospitals Pvt Ltd and Apollo Fertility Centre Pvt Ltd are no longer subsidiaries of Apollo Health and Lifestyle Limited.
- Dr. Madhu Sasidhar to step down as President & CEO – Hospitals Division on November 14, 2026.
- Board approved unaudited financial results for the six months ended September 30, 2026.
- Revenue from operations for six months was Rs 55,590 million and profit after tax was Rs 8,607 million.
Key Data Snapshot
What happened
- Apollo Hospitals Enterprise Limited completed the divestment of its entire shareholding in Apollo Specialty Hospitals Private Limited and Apollo Fertility Centre Private Limited to Kids Clinic India Limited.
- The transaction was successfully closed on 3 November 2026, with Apollo Health and Lifestyle Limited receiving Rs 7,650 million in cash and an approximate 9.9% equity stake in Kids Clinic India Limited valued at Rs 3,850 million.
- Following the divestment, the two companies ceased to be subsidiaries of Apollo Health and Lifestyle Limited.
Key details
- The total enterprise value of the transaction was approximately Rs 11,500 million.
- Dr. Madhu Sasidhar will step down as President & CEO – Hospitals Division effective from 14 November 2026 after completion of his employment tenure.
- Senior management appointments include Dr. Ritu Garg as CEO for multi-regions, Dr. N. Venkatesan as Chief Procurement Officer, and Mr. Anand Wasker as Chief Business Officer - International.
- Post-divestment, support functions and other regions previously reporting to the Hospitals Division CEO will now report to the Project Management Office under the Managing Director.
Financial performance
- For the six months ended 30 September 2026, Apollo Hospitals reported revenue from operations of Rs 55,590 million.
- Profit after tax for the same period was Rs 8,607 million.
- The results are unaudited and have been subjected to limited review by the statutory auditors.
Regulatory and governance context
- The financial results and limited review reports are published in accordance with SEBI Listing Regulations 2015.
- This information has also been disclosed to the National Stock Exchange and Bombay Stock Exchange.
Highlights
- Divestment completed on November 3, 2026, at Rs 11,500 million enterprise value.
- Received Rs 7,650 million cash and 9.9% equity stake in Kids Clinic India Limited valued at Rs 3,850 million.
- Apollo Specialty Hospitals Pvt Ltd and Apollo Fertility Centre Pvt Ltd are no longer subsidiaries of Apollo Health and Lifestyle Limited.
- Dr. Madhu Sasidhar to step down as President & CEO – Hospitals Division on November 14, 2026.
- Board approved unaudited financial results for the six months ended September 30, 2026.
- Revenue from operations for six months was Rs 55,590 million and profit after tax was Rs 8,607 million.
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
More News on Investor Presentation
View allLatest corporate announcements and market updates in Investor Presentation.
Anthem Biosciences to Participate in JM Financial India Xchange 2026 Analyst Meetings in Mumbai
Anthem Biosciences Limited announced its scheduled participation in the JM Financial India Xchange 2026, featuring group and one-on-one meetings with analysts and institutional investors from November 16 to 18, 2026, in Mumbai.
Read Full Story
Berger Paints India Achieves 11.9% Standalone Revenue Growth in Q2 FY27 Amid Raw Material Cost Pressures
Berger Paints India Limited recorded an 11.9% standalone revenue increase in the quarter ended 30 September 2026, with consolidated PBDIT rising 5.2%. The Decorative segment showed near double-digit value growth, while margins were pressured by raw material inflation and pricing delays.
Read Full Story
Uno Minda Limited Posts 38% Revenue Growth and Rs 420 Cr PAT in Q2 FY27
Uno Minda Limited announced a 38% year-on-year increase in consolidated revenues to Rs 6,655 crore and a 38% rise in profit after tax to Rs 420 crore for Q2 FY27 in its investor presentation dated November 5, 2026.
Read Full Story
